• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Recurrence of endometrial hyperplasia following medical therapy is common

byDenise PongandLeah Hawkins Bressler, MD, MPH
December 6, 2015
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Many women developed recurrence, most within the first 6 months after cessation of therapy.

2. There were no differences in relapse rate between the 3 treatment arms.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Endometrial cancer is the most common gynecologic malignancy affecting women in the U.S. The primary risk factor is exposure to excess, unopposed estrogen. The most common cause of excess estrogen is endogenous estrogen production from peripheral conversion via aromatase in obese women. Endometrial hyperplasia, the precursor to cancer, is categorized as simple without atypia, complex without atypia, simple with atypia, and complex with atypia. Women with atypical histology are more likely to develop endometrial cancer. Definitive treatment requires hysterectomy. For women who wish to preserve fertility or who do not desire surgical management, they may be treated with progestin therapy in the form of medroxyprogesterone acetate (MPA) or a levonorgestrel-releasing intrauterine device (LNG-IUD). Prior studies have found that the treatment response rate with LNG-IUD is superior to that with oral MPA. Investigations evaluating the rate of relapse after treatment have yielded unclear results. In the present work, authors evaluated recurrence of hyperplasia over 24 months following treatment with LNG-IUD or MPA therapy in a multi-center randomized trial. They found high rates of recurrence but no difference in the rate or timing of relapse between treatment groups.

Strengths of the study included multicenter, randomized controlled trial (RCT) design. The study was limited by small sample size and potential confounding among women who received additional progestin therapy outside of the trial regimen. Further RCTs are needed to identify the optimal duration of therapy and frequency of post-therapy monitoring for women receiving progestin therapy for endometrial hyperplasia.

Click to read the study in BJOG

Relevant Reading: Prediction of regression and relapse of endometrial hyperplasia with conservative therapy

RELATED REPORTS

Lenvatinib plus pembrolizumab increased survival for advanced endometrial cancer patients when compared to chemotherapy

Quick Take: Pregnancy duration and endometrial cancer risk

2 Minute Medicine Rewind August 19, 2019

In-Depth [randomized controlled trial]: This study compared the rate of recurrence of endometrial hyperplasia following treatment among women randomized to receive therapy for 6 months with LNG-IUD (n = 53), 10mg oral MPGA 10 days per cycle (n = 52), and 10mg oral MPA daily (n = 48). The primary outcome of interest was relapse of endometrial hyperplasia as detected by light microscopy.

Of the 135 women completing therapy, 135 had response to therapy. In the 24-month follow-up period, 41% had histological relapse; 63.6% of these relapses occurred within 6 months of cessation of therapy. No differences in relapse were observed between the 3 treatment regimens (p = 0.66). Menopausal status (p = 0.0005) and estrogen level (p = 0.0007) were associated with relapse.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: endometrial cancer
Previous Post

Tramadol and Celecoxib effective pain control for hysteroscopy

Next Post

Cesarean delivery for term breech not associated with long-term benefit [Classics Series]

RelatedReports

Recurrence of endometrial hyperplasia following medical therapy is common
Oncology

Lenvatinib plus pembrolizumab increased survival for advanced endometrial cancer patients when compared to chemotherapy

March 27, 2022
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity
Obstetrics

Quick Take: Pregnancy duration and endometrial cancer risk

September 1, 2019
2 Minute Medicine Rewind August 19, 2019
Weekly Rewinds

2 Minute Medicine Rewind August 19, 2019

August 28, 2019
Recurrence of endometrial hyperplasia following medical therapy is common
Obstetrics

Laparoscopic hysterectomy equivalent to abdominal hysterectomy in disease-free and overall survival

March 31, 2017
Next Post
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

Cesarean delivery for term breech not associated with long-term benefit [Classics Series]

USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy

Inter-pregnancy weight gains linked to increased risks of stillbirth and infant mortality

2 Minute Medicine Physician Press Podcast - December 2015

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.